Osteoporosis: Part II. Nonpharmacologic and Pharmacologic Treatment



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 2001 Mar 15;63(6):1121-1129.

  This is part II of a two-part article on osteoporosis. Part I, “Evaluation and Assessment,” appeared in the previous issue (Am Fam Physician 2000;63: 897–904,908).

Family physicians will frequently encounter patients with osteoporosis, a condition that is often asymptomatic until a fracture occurs. Treatment of the fracture can be initiated without further diagnostic testing. Thereafter, treatment of osteoporosis includes (1) prevention of further bone loss through weight-bearing exercise, tobacco and alcohol avoidance, hormone replacement therapy in women, and raloxifene and calcium supplementation; (2) treatment of fracture-related pain with analgesics and calcitonin; (3) building bone mass when feasible with alendronate; and (4) modifying behaviors that increase the risk of falls. Patients without fracture who are at risk for osteoporosis can also benefit from these preventive measures. Furthermore, women of all ages should be encouraged to maintain a daily calcium intake of 1,000 to 1,500 mg and to participate in weight-bearing exercise for 30 minutes three times weekly to reduce their risk of falls and fractures. Persons at risk should avoid medications known to compromise bone density, such as glucocorticoids, thyroid hormones and chronic heparin therapy.

To prevent the problem of osteoporosis-related fractures, family physicians and other primary health care professionals should emphasize prevention in younger patients and select appropriate therapies for use in those who are already affected.

The approach to the patient is governed by the presentation. The greatest challenge for clinicians is to know which asymptomatic patients would benefit from screening for osteoporosis, rather than merely to determine a treatment regimen for those with known disease. All women and girls should be counseled concerning calcium intake and physical activity. Assessment of osteoporosis risk is also important when following a patient for a chronic disease known to cause secondary osteoporosis. Preventive measures are always the first step in therapy.

If the physician suspects osteoporosis in a man or finds evidence of a pathologic fracture in a man or a woman, the next steps are to assess the patient's risk by taking a medical history and to determine bone mineral density (BMD). BMD measurement and laboratory evaluation are necessary to document the extent of bone loss and rule out secondary causes of osteoporosis. If there is clinical evidence of a particular condition, the focus of the evaluation can shift to the suspected condition once the basic laboratory study has been completed.

Behavior Modification

Patients requesting risk assessment for osteoporosis may require only a history and physical examination, and the provision of patient information. Patients at risk for osteoporosis should be counseled about behavioral measures that can decrease their risk of bone loss. Tobacco use and excessive consumption of alcohol and caffeine should be discouraged.1 A balanced diet with adequate calcium and vitamin D intake and a regular exercise program (see below) should be encouraged to retard bone loss. The use of medications (e.g., glucocorticoids) that decrease bone mass should be avoided, if possible. The importance of maintaining estrogen levels in women should be emphasized. Measurement of bone density should be considered in patients who present with risk factors but need “proof” before agreeing to take preventive measures.

Exercise

More than 20 randomized, controlled trials2 suggest that regular physical exercise can reduce the risk of osteoporosis and delay the physiologic decrease of BMD. Short-term and long-term (measured up to 12 months) exercise training such as walking, jogging and stair climbing in healthy, sedentary postmenopausal women resulted in improved bone mineral content.3 Bone mineral content increased more than 5 percent above baseline after short-term weight-bearing exercise training. With reduced weight-bearing exercise, bone mass soon reverted to baseline levels.4,5 Similar increases in BMD have been found in women who participate in strength training.6 In the elderly, progressive strength training has been demonstrated to be a safe and effective form of exercise that reduces risk factors for falling and may also enhance BMD.7

Athletes who exercise regularly usually have above-average bone mass. However, the positive effect of exercise on the bones of young women is dependent on normal levels of endogenous estrogen. The low estrogen state of exercise-induced amenorrhea outweighs the positive effects of exercise and results in diminished bone density. When mechanical stress or gravitational force on the skeleton is removed (e.g., bed rest, immobilization of limbs or paralysis), bone loss is rapid and extensive.8

Estrogen deficiency results in diminished bone density in women. Weight-bearing exercise can significantly increase the BMD of menopausal women.5 Furthermore, weight-bearing exercise and estrogen replacement therapy (ERT) have independent and additive effects on the BMD of the limbs, spine and Ward's triangle (hip).

No randomized, prospective studies have systematically compared the effect of various activities on bone mass. Recommended activities include walking and jogging, weight training, aerobics, stair climbing, field sports, racquet sports, court sports and dancing. Swimming is of questionable value in terms of bone density (because it is not a weight-bearing activity), and there are no data on cycling, skating or skiing. Any increase in physical activity may have a positive effect on bone mass in women who have been sedentary. To be beneficial, the duration of exercise should be between 30 and 60 minutes and the frequency at least three times per week.

Pharmacologic Therapy

ESTROGEN

The decision to intervene with pharmacologic therapy involves clinical judgment based on a global assessment, not just BMD measurement. All therapeutic agents currently approved for the prevention and treatment of osteoporosis work through inhibiting or decreasing bone resorption. Maintaining adequate estrogen levels remains the most important way of maintaining adequate bone density in women.9,10  All women with decreased bone density should be offered estrogen replacement therapy (ERT) unless contraindications exist. The most common contraindications are listed in Table 1.11 Conjugated estrogens in dosages of 0.625 and 1.25 mg per day and transdermal estrogen (a weekly patch containing 0.05 mg) are equally effective in reducing bone loss in postmenopausal and oophorectomized women.12

TABLE 1

Contraindications to ERT for Osteoporosis

Absolute contraindications

History of breast cancer

Estrogen-dependent neoplasia

Undiagnosed or abnormal vaginal bleeding

History of or active thromboembolic disorder

Relative contraindications

Migraine

History of thromboembolism

Familial hypertriglyceridemia

Uterine leiomyomas

Uterine cancer

Gall bladder disease

Strong family history of breast cancer

Chronic hepatic dysfunction

Endometriosis


ERT = estrogen replacement therapy.

Reprinted with permission from Scientific Advisory Board, Osteoporosis Society of Canada. Clinical practice guidelines for the diagnosis and management of osteoporosis. CMAJ 1996;155:1113–33.

TABLE 1   Contraindications to ERT for Osteoporosis

View Table

TABLE 1

Contraindications to ERT for Osteoporosis

Absolute contraindications

History of breast cancer

Estrogen-dependent neoplasia

Undiagnosed or abnormal vaginal bleeding

History of or active thromboembolic disorder

Relative contraindications

Migraine

History of thromboembolism

Familial hypertriglyceridemia

Uterine leiomyomas

Uterine cancer

Gall bladder disease

Strong family history of breast cancer

Chronic hepatic dysfunction

Endometriosis


ERT = estrogen replacement therapy.

Reprinted with permission from Scientific Advisory Board, Osteoporosis Society of Canada. Clinical practice guidelines for the diagnosis and management of osteoporosis. CMAJ 1996;155:1113–33.

Studies have been made of the effect of the timing of initiation and the duration of post-menopausal estrogen therapy on BMD.13,14 Current users who started ERT at menopause had the highest BMD levels, which were significantly higher than “never” users or “past” users who started at menopause and continued it for at least 10 years. BMD was similar in women using unopposed estrogen or estrogen plus progestin, in women younger or older than 75 years and in current smokers or nonsmokers.

Current users who started ERT within five years of menopause had a decreased risk of hip, wrist and all nonspinal fractures compared with those who never used estrogen. Long-term users who initiated therapy five years after menopause had no significant reduction in risk for all nonspinal fractures, despite an average duration of use of 16 years.13 Therefore, early initiation of ERT with respect to menopause may be more important than the total duration of use. Estrogen initiated early in menopause and continued into late life appears to be associated with the highest bone density.

As more and more women use ERT, concern has grown regarding its impact on breast cancer risk. The relationship between the use of hormones and the risk of breast cancer in postmenopausal women was assessed in a follow-up survey of participants in the Nurses' Health Study in 1992.15 The risk of breast cancer was found to be significantly increased among women who were currently using estrogen alone or estrogen plus progestin, compared with postmenopausal women who had never used hormones. The risk of breast cancer in women currently taking hormones was increased by the same proportions if they had used hormones in the past for five to nine years or for 10 or more years.15 The addition of progestins to estrogen therapy does not reduce the risk of breast cancer among post-menopausal women.

The only randomized trial of estrogen-progesterone therapy describes secondary prevention of coronary heart disease in post-menopausal women (HERS) and included only women with a prior history of cardiovascular disease.16,17 Women received either estrogen or estrogen and progesterone. There was an excess of coronary heart disease deaths and a threefold excess risk of venous thrombosis during the first year of the trial in women taking estrogen and a small risk of stroke in women taking estrogen and progesterone. Recommendations at the conclusion of the trial included forgoing estrogen and progesterone therapy in women who already have clinical cardiovascular disease (i.e., secondary prevention).

CALCIUM AND VITAMIN D

Calcium supplementation results in small beneficial effects on bone mass throughout postmenopausal life and may reduce fracture rates by more than the change in BMD would predict—possibly as much as 50 percent.18 Postmenopausal women receiving supplemental calcium over a three-year period in a placebo-controlled, randomized clinical trial19 had stable total body calcium levels and BMD in the lumbar spine, femoral neck and trochanter compared with women in the placebo group.

Vitamin D increases calcium absorption in the gastrointestinal tract, so that more calcium is available in the circulation and subsequently reabsorbed in the renal proximal tubules. Evidence shows there are significant reductions in nonvertebral fracture rates as a result of physiologic replacement of vitamin D in the elderly.18 Vitamin D supplementation is important in women of all ages who have limited exposure to sunlight.

Dietary calcium augmentation should be recommended to maintain lifetime calcium levels and to prevent early postmenopausal bone loss. Foods that are rich in calcium are listed in Table 2.20 Most adults should ingest 1,000 mg of elemental calcium per day for optimal bone health.11,21 Teenagers, pregnant or lactating women, women older than 50 years who are taking ERT, and everyone older than 65 years should ingest 1,500 mg of elemental calcium per day for optimal bone health. If this cannot be achieved by diet alone, calcium supplementation is recommended. Calcium preparations should be compared relative to elemental calcium content. Therefore, it is important that the physician pay attention to the particular form of calcium supplement the patient is taking.

TABLE 2

Calcium-Rich Foods*

Milk (skim, low-fat or whole), 8 oz

Plain yogurt, 8 oz

Frozen yogurt with fruit, 8 oz

Ricotta cheese, part-skim, 4 oz

Sardines, canned, 3 oz

Cooked greens (collards or mustard), 8 oz

Firm cheeses (swiss, edam, brick, cheddar, gouda, colby, mozzarella), 1 oz

Calcium-fortified orange juice, 8 oz


*—Approximately 300 mg per amount listed.

Adapted with permission from Tresolini CP, Gold DT, Lee LS, eds. Working with patients to prevent, treat and manage osteoporosis: a curriculum guide for health professions. 2d ed. San Francisco: National Fund for Medical Education, 1998.

TABLE 2   Calcium-Rich Foods*

View Table

TABLE 2

Calcium-Rich Foods*

Milk (skim, low-fat or whole), 8 oz

Plain yogurt, 8 oz

Frozen yogurt with fruit, 8 oz

Ricotta cheese, part-skim, 4 oz

Sardines, canned, 3 oz

Cooked greens (collards or mustard), 8 oz

Firm cheeses (swiss, edam, brick, cheddar, gouda, colby, mozzarella), 1 oz

Calcium-fortified orange juice, 8 oz


*—Approximately 300 mg per amount listed.

Adapted with permission from Tresolini CP, Gold DT, Lee LS, eds. Working with patients to prevent, treat and manage osteoporosis: a curriculum guide for health professions. 2d ed. San Francisco: National Fund for Medical Education, 1998.

CALCITONIN

Calcitonin (Calcimar), a hormone directly inhibiting osteoclastic bone resorption, is an alternative for use in patients with established osteoporosis who cannot, will not or should not proceed with ERT.21 A unique characteristic of calcitonin is that it produces an analgesic effect with respect to bone pain and, thus, is often prescribed for patients who have had an acute osteoporotic fracture. Calcitonin decreases further bone loss at vertebral and femoral sites in patients with documented osteoporosis but has a questionable effect on fracture frequency. Calcitonin has been shown to prevent trabecular bone loss during the first few years of menopause, but it is unclear whether it has any impact on cortical bone.18 Calcitonin is also thought to be effective in decreasing the fracture rate of vertebrae and peripheral bones.22

For reasons that are poorly understood, the increase in BMD associated with calcitonin administration may be transient or resistance may develop. Calcitonin can be provided in two forms, as a nasal inhaler and as an injection. Nasal congestion and rhinitis are the most significant side effects of the nasal form. The injectable formulation has gastrointestinal side effects and is less convenient to use than the nasal preparation. The increase in bone density resulting from this therapy is significantly less than that achieved by alendronate (Fosamax) or estrogen, and may be limited to the spine, but it still has value in reducing the risk of fracture.

BISPHOSPHONATES

Bisphosphonates are effective for preventing bone loss associated with estrogen deficiency, glucocorticoid treatment and immobilization.23 All bisphosphonates act similarly on bone in binding permanently to mineralized bone surfaces and inhibiting osteoclastic activity. Thus, less bone is degraded during the remodeling cycle.23,24

The Fracture Intervention Trial25 investigated the effect of alendronate on the risk of fractures (inapparent fractures as well as clinically evident fractures) in postmenopausal women with low bone mass. The risk of clinical fracture in those taking alendronate was one half that of women in the placebo group.

Because food and liquids can reduce the absorption of alendronate (Fosamax), it should be taken with a full glass of water 30 minutes before the first meal or beverage of the day. To lessen the chance of esophageal irritation, patients should not lie down for at least 30 minutes after taking the dose. In addition, patients should consider taking supplemental calcium and vitamin D if their dietary intake is inadequate.

Alendronate and ERT are of comparable efficacy in preventing bone loss; alendronate has a demonstrated positive effect on symptomatic and asymptomatic vertebral fracture rate, as well as on the nonvertebral fracture rate (forearm and hip).18,25 In clinical trials, alendronate was generally well tolerated and caused no significant adverse effects. Alendronate appears to be effective at dosages of 5 mg per day in preventing osteoporosis induced by long-term glucocorticoid therapy. In placebo-controlled studies26 of men and women (17 to 83 years of age) who were taking glucocorticoids, the bone density of the femoral neck bone, the trochanter and the total body increased significantly in patients treated with alendronate.

Some small studies27 suggest an additional benefit of adding alendronate to ERT. However, all of the bisphosphonates accumulate in bone over time, and further research is needed to determine their long-term impact, as well as their potential for use in men and premenopausal women.

SELECTIVE ESTROGEN RECEPTOR MODULATORS

Raloxifene (Evista) is the first drug from a new class—selective estrogen receptor modulators—to be studied in the treatment of osteoporosis. Its discovery evolved from a rearrangement of the anti-estrogen tamoxifen (Nolvadex). Raloxifene is thought to block estrogen in a similar manner while also binding and stimulating other estrogen tissue receptors. Raloxifene inhibits trabecular and vertebral bone loss by blocking the activity of cytokines, which stimulate bone resorption.

Raloxifene therapy results in decreased serum total and low-density lipoprotein (LDL) cholesterol levels without having any beneficial effects on serum high-density lipoprotein (HDL) cholesterol or triglyceride levels.28,29 Reported side effects of raloxifene are vaginitis and hot flushes.30 Investigators in a trial31 of more than 7,000 postmenopausal osteoporotic women studied over three years showed a decreased breast cancer risk in those who were already at low risk for the disease. Studies of women at higher risk for breast cancer are currently under way.

A summary of overall treatment strategies is presented in Table 3,32  and guidelines for dosing are presented in Table 4.

TABLE 3

Treatment Guidelines for Osteoporosis

Overall strategies

Calcium supplements, with or without vitamin D supplements, or calcium-rich diet

Weight-bearing exercise

Avoidance of alcohol, tobacco products, drugs and excessive caffeine

ERT within five years of menopause for 10+ years

Alendronate (Fosamax)

Raloxifene (Evista)

Strategies for patients taking glucocorticoids

Lowest dosage of a short-acting glucocorticoid or use of topical preparations whenever possible

Well-balanced diet, with daily intake of 2 to 3 g of sodium

Weight-bearing and isometric exercise to prevent proximal muscle weakness

Calcium intake of 1,500 mg per day and vitamin D intake of 400 to 800 IU per day after hypercalciuria is controlled

ERT in all postmenopausal women and in premenopausal women with low levels of estradiol

Measurement of BMD at baseline and every six to 12 months during the first two years of therapy to assess treatment efficacy

Treatment with calcitonin or bisphosphonate if bone loss occurs during treatment or if ERT is contraindicated


ERT = estrogen replacement therapy; BMD = bone mineral density.

Adapted with permission from Lane NE, Lukert B. The science and therapy of glucocorticoid-induced bone loss. Endocrinol Metab Clin North Am 1998;27:465–83.

TABLE 3   Treatment Guidelines for Osteoporosis

View Table

TABLE 3

Treatment Guidelines for Osteoporosis

Overall strategies

Calcium supplements, with or without vitamin D supplements, or calcium-rich diet

Weight-bearing exercise

Avoidance of alcohol, tobacco products, drugs and excessive caffeine

ERT within five years of menopause for 10+ years

Alendronate (Fosamax)

Raloxifene (Evista)

Strategies for patients taking glucocorticoids

Lowest dosage of a short-acting glucocorticoid or use of topical preparations whenever possible

Well-balanced diet, with daily intake of 2 to 3 g of sodium

Weight-bearing and isometric exercise to prevent proximal muscle weakness

Calcium intake of 1,500 mg per day and vitamin D intake of 400 to 800 IU per day after hypercalciuria is controlled

ERT in all postmenopausal women and in premenopausal women with low levels of estradiol

Measurement of BMD at baseline and every six to 12 months during the first two years of therapy to assess treatment efficacy

Treatment with calcitonin or bisphosphonate if bone loss occurs during treatment or if ERT is contraindicated


ERT = estrogen replacement therapy; BMD = bone mineral density.

Adapted with permission from Lane NE, Lukert B. The science and therapy of glucocorticoid-induced bone loss. Endocrinol Metab Clin North Am 1998;27:465–83.

TABLE 4

Agents for Treating Osteoporosis

Medication Dosage Route Cost*

Estradiol skin patch (Estraderm)

0.05 mg every week

Topical

$26 to 68

Conjugated estrogens

0.625 to 1.25 mg per day

Oral

16 to 23

Elemental calcium

1,000 to 1,500 mg per day

Oral

13 to 20

Calcitonin (Calcimar)

200 IU per day or 50 to 100 IU per day

Intranasal or subcutaneous/ intramuscular

36 to 59

Vitamin D

400 IU per day (800 IU per day in winter in northern latitudes)

Oral

1

Alendronate (Fosamax)

Prevention: 5 mg per day

Oral

61 (5 mg)

Treatment: 10 mg per day

61 (10 mg)

Raloxifene (Evista)

60 mg per day

Oral

61


*—Estimated cost to the pharmacist based on average wholesale prices for one month of therapy (rounded to the nearest dollar) in Red book. Montvale, N.J.: Medical Economics Data, 2000. Cost to the patient will be greater, depending on prescription filling fee.

TABLE 4   Agents for Treating Osteoporosis

View Table

TABLE 4

Agents for Treating Osteoporosis

Medication Dosage Route Cost*

Estradiol skin patch (Estraderm)

0.05 mg every week

Topical

$26 to 68

Conjugated estrogens

0.625 to 1.25 mg per day

Oral

16 to 23

Elemental calcium

1,000 to 1,500 mg per day

Oral

13 to 20

Calcitonin (Calcimar)

200 IU per day or 50 to 100 IU per day

Intranasal or subcutaneous/ intramuscular

36 to 59

Vitamin D

400 IU per day (800 IU per day in winter in northern latitudes)

Oral

1

Alendronate (Fosamax)

Prevention: 5 mg per day

Oral

61 (5 mg)

Treatment: 10 mg per day

61 (10 mg)

Raloxifene (Evista)

60 mg per day

Oral

61


*—Estimated cost to the pharmacist based on average wholesale prices for one month of therapy (rounded to the nearest dollar) in Red book. Montvale, N.J.: Medical Economics Data, 2000. Cost to the patient will be greater, depending on prescription filling fee.

OTHER MODALITIES

Fluoride increases bone formation by stimulating osteoblasts and increasing cancellous bone formation in patients with osteoporosis. However, the bone is formed only in the spine and is irregularly fibrous and woven with lacunae of low mineral density.33 Cessation of therapy results in rapid loss of much of the bone formed during treatment. The major side effect of fluoride therapy, gastric distress, may be related to the direct effect of hydrofluoric acid on the gastric mucosa.

Several other drugs have been studied in the treatment of osteoporosis but for various reasons are not accepted therapies. Anabolic steroids produce some increase in bone mass. Despite this benefit, these drugs are seldom used for treating osteoporosis in the United States because of their long-term effects—significant hepatotoxicity, reduced HDL levels and elevated LDL cholesterol levels.34

COMPLEMENTARY AND ALTERNATIVE THERAPIES

Evidence from animal studies suggests a beneficial effect of phytoestrogens on bone, but long-term human studies are lacking.35 Epidemiologic evidence of Asian women having a lower fracture rate than white women, even though the bone density of Asian women is less than that of black women, promotes consideration of the impact of nutrition. It is possible that a high dietary soy intake contributes to improved bone quality in Asian women. A comparison study of a soy protein-high isoflavone diet versus a milk protein or a medium isoflavone-soy protein diet demonstrated that those receiving high isoflavone supplementation had a modest increase in trabecular (vertebral) bone, but not in cortical (femoral) bone.36

A topical form of natural progesterone derived from diosgenin in soybeans and Mexican wild yam has been promoted as a treatment for osteoporosis, hot flushes and premenstrual syndrome, and as a prophylactic against breast cancer. However, humans cannot convert diosgenin into progesterone, so eating or applying wild yam extract or diosgenin does not result in increased progesterone levels.37

GLUCOCORTICOID-INDUCED OSTEOPOROSIS

Glucocorticoids are widely used in the treatment of many chronic diseases, particularly asthma, lung disease and inflammatory and rheumatologic disorders, as well as in patients who have undergone organ transplantation. To achieve the best possible outcome for these patients given the potentially devastating effects of systemic steroids, therapy to combat their effects on osteoporosis should begin as soon as the steroid therapy is begun. Table 332 presents specific guidelines for therapy in these patients.

The opinions and assertions contained herein are the private views of the author and are not to be construed as official or as reflecting the views of the Army Medical Department or the Army Service at large

.

 

REFERENCES

1. Taxel P. Osteoporosis: detection, prevention, and treatment in primary care. Geriatrics. 1998;53(8):22–33.

2. Ernst E. Exercise for female osteoporosis. A systematic review of randomised clinical trials. Sports Med. 1998;25:359–68.

3. Dalsky GP, Stocke KS, Ehsani AA, Slatopolsky E, Lee WC, Birge SJ. Weight-bearing exercise training and lumbar bone mineral content in post-menopausal women. Ann Intern Med. 1988;108:824–8.

4. Chow R, Harrison JE, Notarius C. Effect of two randomised exercise programmes on bone mass of healthy postmenopausal women. Br Med J [Clin Res]. 1987;295(6611):1441–4.

5. Kohrt WM, Snead DB, Slatopolsky E, Birge SJ. Additive effects of weight-bearing exercise and estrogen on bone mineral density in older women. J Bone Miner Res. 1995;10:1303–11.

6. Nelson ME, Fiatarone MA, Morganti CM, Trice I, Greenberg RA, Evans WJ. Effects of high-intensity strength training on multiple risk factors for osteoporotic fractures. JAMA. 1994;272:1909–14.

7. Henderson NK, White CP, Eisman JA. The roles of exercise and fall risk reduction in the prevention of osteoporosis. Endocrinol Metab Clin North Am. 1998;27:369–87.

8. Drinkwater BL. Physical exercise and bone health. J Am Med Wom Assoc. 1990;45:91–7.

9. Umland EM, Rinaldi C, Parks SM, Boyce EG. The impact of estrogen replacement therapy and raloxifene on osteoporosis, cardiovascular disease, and gynecologic cancers. Ann Pharmacother. 1999;33:1315–28.

10. Ravn P, Bidstrup M, Wasnich RD, Davis JW, McClung MR, Balske A, et al. Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early post-menopausal intervention cohort study. A randomized, controlled trial. Ann Intern Med. 1999;131:935–42.

11. Scientific Advisory Board, Osteoporosis Society of Canada. Clinical practice guidelines for the diagnosis and management of osteoporosis. CMAJ. 1996;155:1113–33.

12. Lindsay R, Hart DM, Clark DM. The minimum effective dose of estrogen for prevention of post-menopausal bone loss. Obstet Gynecol. 1984;63:759–63.

13. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. Estrogen replacement therapy and fractures in older women. Ann Intern Med. 1995;122:9–16.

14. Schneider DL, Barrett-Connor EL, Morton DJ. Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernardo Study. JAMA. 1997;277:543–7.

15. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995;332:1589–93.

16. Kuller LH. Hormone replacement therapy and coronary heart disease: a new debate. Med Clin North Am. 2000;84:181–98.

17. Petitti DB. Hormone replacement therapy and heart disease prevention: experimentation trumps observation. JAMA. 1998;280:650–2.

18. Reid IR. The role of calcium and vitamin D in the prevention of osteoporosis. Endocrinol Metab Clin North Am. 1998;27:389–98.

19. Aloia JF, Vaswani A, Yeh JK, Ross PL, Flaster E, Dilmanian FA. Calcium supplementation with and without hormone replacement therapy to prevent postmenopausal bone loss. Ann Intern Med. 1994;120:97–103.

20. Tresolini CP, Gold DT, Lee LS, eds. Working with patients to prevent, treat and manage osteoporosis: a curriculum guide for health professions. 2d ed. San Francisco: National Fund for Medical Education, 1998.

21. Avioli LV. The role of calcitonin in the prevention of osteoporosis. Endocrinol Metab Clin North Am. 1998;27:411–8.

22. Overgaard K, Hansen MA, Jensen SB, Christiansen C. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose response study. BMJ. 1992;305:556–61.

23. Watts NB. Treatment of osteoporosis with bisphosphonates. Endocrinol Metab Clin North Am. 1998;27:419–39.

24. Devogelaer JP. A risk-benefit assessment of alendronate in the treatment of involutional osteoporosis. Drug Saf. 1998;19:141–54.

25. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348:1535–41.

26. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med. 1998;339:292–9.

27. Kirk JK, Spangler JG. Alendronate: a bisphosphonate for treatment of osteoporosis. Am Fam Physician. 1996;54:2053–60.

28. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in post-menopausal women. N Engl J Med. 1997;337:1641–7.

29. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C. A controlled trial of raloxifene (LY139481) HCL: impact on bone turnover and serum lipid profile in healthy post-menopausal women. J Bone Miner Res. 1996;11:835–42.

30. Wilhite SL, Scoggin JA. Raloxifene provides an alternative for osteoporosis prevention. Ann Pharmacother. 1998;32:834–7.

31. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA. 1999;281:2189–97.

32. Lane NE, Lukert B. The science and therapy of glucocorticoid-induced bone loss. Endocrinol Metab Clin North Am. 1998;27:465–83.

33. Kleerekoper M. The role of fluoride in the prevention of osteoporosis. Endocrinol Metab Clin North Am. 1998;27:441–52.

34. Reginster JY, Taquet AN, Gosset C. Therapy for osteoporosis. Miscellaneous and experimental agents. Endocrinol Metab Clin North Am. 1998;27:453–63.

35. Fugh-Berman A. Soybean intake and bone density. Alternative Therapies Women's Health. 1999;1(4):25–32.

36. Potter SM. Soy protein and isoflavones: their effects on blood lipids and bone density in post-menopausal women. Am J Clin Nutr. 1998;68(6 suppl):1375S–9S.

37. Fugh-Berman A. Progesterone cream for osteoporosis. Alternative Therapies Women's Health. 1999;1(5):33–40.

Members of various family practice departments develop articles for “Problem-Oriented Diagnosis.” This article is one in a series coordinated by the Department of Family Medicine at the Uniformed Services University of the Health Sciences, Bethesda, Md. Guest editors of the series are Francis G. O'Connor, LTC, MC, USA, and Jeannette E. South-Paul, COL, MC, USA.


Copyright © 2001 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Download PDF
  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in Pubmed

Navigate this Article